Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity

PHASE2CompletedINTERVENTIONAL
Enrollment

279

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

December 31, 2004

Study Completion Date

December 31, 2004

Conditions
StrokeMuscle Spasticity
Interventions
BIOLOGICAL

Botulinum Toxin Type A

Each patient received from 1 to 5 treatments, with a minimum of 12 weeks between treatments. For each treatment, a total dose of 200 U to 400 U botulinum toxin Type A was injected into the wrist and finger flexor muscles of the affected upper limb, not to exceed 6 U/kg

Trial Locations (2)

Unknown

Indianapolis

Vancouver

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY